Financial Disclosure: Dr. Manal F. Abdelmalek — MASH Educational Initiative
This is a disclosure statement for Dr. Manal F. Abdelmalek, a professor and director of the MASLD Clinical Research Program at Mayo Clinic, listing her relevant financial relationships with pharmaceutical companies including 89Bio, Boehringer Ingelheim, Hanmi, Inventiva, Madrigal Pharmaceuticals, and Novo Nordisk. The content is part of an educational initiative aimed at providing clinicians with tools to manage MASH (metabolic dysfunction-associated steatohepatitis) in the modern era.
Key quotes
This educational initiative gives clinicians the tools they need to manage MASH in the modern era.
Consultant or advisor for: 89Bio; Boehringer Ingelheim; Hanmi; Inventiva; Madrigal Pharmaceuticals; Novo Nordisk
Research funding from: 89Bio; Akero Therapeutics; Hanmi; Inventiva; Madrigal; Novo Nordisk
You might also wanna read
Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians
Nutrition Intervention Combined With Resmetirom for MASH
Angptl4 integrates dietary and microbial signals to disrupt gut barrier function in MASH
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Markwayne Mullin's kratom industry investments raise conflict of interest concerns
A New York Times report reveals that Homeland Security Secretary Markwayne Mullin, while serving as a senator from Oklahoma, played a signif
ms.now·13d ago
Goldman Sachs Report Questions Financial Sustainability of Curative Gene Therapies
Goldman Sachs analysts question whether curing patients is a sustainable business model for biotech companies, particularly those developing
cnbc.com·7mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.